Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ITGB1

ITGB1

Basics

Aliases:
This biomarker is also known as:
  • integrin beta-1,
  • MDF2,
  • GPIIA,
  • FNRB,
  • Fibronectin receptor subunit beta,
  • MSK12,
  • VLA-4 subunit beta,
  • VLA-BETA,
  • CD29,
  • VLAB,
  • integrin VLA-4 beta subunit,
  • CD29 antigen,
  • integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12),
  • very late activation protein, beta polypeptide,

View in BioMuta

Description…

ITGB1 is a beta subunit of the heterodimeric integrin protein. Integrins are ubiquitously expressed adhesion molecules composed of alpha and beta subunits. In mammals, 18 alpha and 8 beta subunits have been identified. Integrin family members are membrane receptors involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells. Several protein isoforms have been identifed, arising from alternatively spliced transcript variants.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data is available.

Performance Comment

ITGB1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html